Table 1 Headache relief after intravenous and oral lasmiditan, subcutaneous and oral sumatriptan, and oral LY334370 in randomised, clinical trials (RCTs) [7, 15, 17, 20]
Drug | Headache relief for active drug at 2 h (%) | Headache relief for placebo at 2 h (%) | Therapeutic gain (95 % confidence intervals) (%) | NNT (number needed to treat) |
|---|---|---|---|---|
Intravenous lasmiditan 20 mg [15] | 64 | 45 | 19 (−4 to 42 %)a | 5.3 |
Oral lasmiditan 400 mg [17] | 64 | 25 | 38 (28 to 51 %) | 2.6 |
Subcutaneous sumatriptan 6 mg [7] | 69 | 19 | 51 (48 to 53 %) | 2.0 |
Oral sumatriptan 100 mg [7] | 61 | 28 | 33 (31 to 35 %) | 3.0 |
LY334370 200 mg [20] | 71 | 19 | 52 (27 to 77 %) | 2.0 |